Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 22,500 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 22,500 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $988,875.00. Following the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at approximately $19,025,339.70. The trade was a 4.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Down 0.2%

Shares of NASDAQ:TVTX opened at $44.70 on Thursday. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $48.61. The business’s 50 day moving average is $32.59 and its 200 day moving average is $32.83.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.Travere Therapeutics’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same period last year, the company posted ($0.47) earnings per share. On average, sell-side analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TVTX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price target on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. Guggenheim lifted their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Citigroup lifted their price target on Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen lowered Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Wedbush lifted their price target on Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Tuesday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year?over?year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long?term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre?arranged Rule 10b5?1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500?share sale) can create short?term selling pressure or investor concern. Example SEC filing: CEO Form 4

Institutional Trading of Travere Therapeutics

Hedge funds have recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Travere Therapeutics in the fourth quarter valued at $37,000. Torren Management LLC bought a new stake in shares of Travere Therapeutics in the fourth quarter valued at $38,000. Comerica Bank raised its stake in shares of Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after buying an additional 492 shares during the period. Fifth Third Bancorp bought a new stake in shares of Travere Therapeutics in the first quarter valued at $35,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after buying an additional 487 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.